Tuesday, October 21, 2014 Last update: 2:33 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

NephroGenex To Participate in Four Healthcare Conferences in September

Companies mentioned in this article: NephroGenex, Inc.

RESEARCH TRIANGLE PARK, N.C. -- (BUSINESS WIRE) -- NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer, Pierre Legault will present an overview of the Company and meet with investors at four healthcare conferences for institutional investors in September.

Rodman & Renshaw 16th Annual Healthcare Conference

  • Location: Palace Hotel, New York City
  • Presentation Date: Tuesday, September 9
  • Presentation Time: 12:05 p.m. EDT

Aegis Capital Corp. 2014 Healthcare Conference

  • Location: The Encore at Wynn Las Vegas Hotel, Las Vegas
  • Presentation Date: Friday, September 12
  • Presentation Time: 8:30 a.m. PDT

Mr. Legault will also conduct a series of one-on-one meetings with investors at the FBR Inaugural Healthcare Conference on September 3, in Boston and at the Biopharm America 2014 Conference in Boston on September 23 and 24.

Live and archived webcasts of the Rodman and Aegis presentations will be accessible from the Company’s new website at http://nephrogenex.investorhq.businesswire.com/events-calendar. A replay will be available for 30 days following the events.

About NephroGenex, Inc.

NephroGenex (NASDAQ: NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. Since our inception, we have collaborated with the leading scientific experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and novel acting drug candidates. Our clinical program has been done in collaboration with world leading clinical investigators in kidney disease. Our product pipeline includes an oral formulation of PYRIDORIN® (pyridoxamine dihydrochloride), which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as an intravenous formulation of Pyridorin to treat specific types of acute kidney injury.

Cautionary Note on Forward-Looking Statements

This press release contains certain statements that are, or may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements regarding the outlook for our future business and financial performance. Forward-looking statements are based on our current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially from those in the forward-looking statements due to global political, economic, business, competitive, market, regulatory and other factors and risks, including the items identified under "Part I—Item 1A—Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission ("SEC") on March 31, 2014, as well as in other filings that we may make with the SEC in the future. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we do not undertake and specifically disclaim any obligation to update any forward-looking statements.


Copyright © Business Wire 2014
Contact:

Investors
Michael Levitan
The Trout Group
646-378-2920
mlevitan@troutgroup.com
or
Media
Susan Duffy
BMC Communications
646-513-3119
sduffy@bmccommunications.com